Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas.
Fiedler W, DeDosso S, Cresta S, Weidmann J, Tessari A, Salzberg M, Dietrich B, Baumeister H, Goletz S, Gianni L, Sessa C. Fiedler W, et al. Among authors: salzberg m. Eur J Cancer. 2016 Aug;63:55-63. doi: 10.1016/j.ejca.2016.05.003. Epub 2016 Jun 7. Eur J Cancer. 2016. PMID: 27285281 Free article. Clinical Trial.
Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas.
Fiedler W, Cresta S, Schulze-Bergkamen H, De Dosso S, Weidmann J, Tessari A, Baumeister H, Danielczyk A, Dietrich B, Goletz S, Zurlo A, Salzberg M, Sessa C, Gianni L. Fiedler W, et al. Among authors: salzberg m. ESMO Open. 2018 Feb 1;3(2):e000303. doi: 10.1136/esmoopen-2017-000303. eCollection 2018. ESMO Open. 2018. PMID: 29464112 Free PMC article.
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer.
Dittrich C, Coudert B, Paz-Ares L, Caponigro F, Salzberg M, Gamucci T, Paoletti X, Hermans C, Lacombe D, Fumoleau P; European Organization for Research and Treatment of Cancer--Early Clinical Studies Group/New Drug Development Programme (EORTC-ECSG/NDDP). Dittrich C, et al. Among authors: salzberg m. Eur J Cancer. 2003 Feb;39(3):330-4. doi: 10.1016/s0959-8049(02)00559-2. Eur J Cancer. 2003. PMID: 12565985 Clinical Trial.
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.
Jermann M, Stahel RA, Salzberg M, Cerny T, Joerger M, Gillessen S, Morant R, Egli F, Rhyner K, Bauer JA, Pless M. Jermann M, et al. Among authors: salzberg m. Cancer Chemother Pharmacol. 2006 Apr;57(4):533-9. doi: 10.1007/s00280-005-0070-z. Epub 2005 Jul 29. Cancer Chemother Pharmacol. 2006. PMID: 16052341 Free article. Clinical Trial.
129 results